MDSCs low | MDSCs high | p | |
---|---|---|---|
Number | 47 | 53 | |
Patient age, median (range) | 32 (5–62) | 30 (2–53) | NS |
Patient sex, male (%) | 30 (63.8%) | 29 (54.7%) | NS |
Diagnosis | NS | ||
AML, n (%) | 21 (44.7%) | 18 (34.0%) | |
ALL, n (%) | 13 (27.7%) | 16 (30.2%) | |
MDS, n (%) | 3 (6.4%) | 5 (9.4%) | |
SAA, n (%) | 6 (12.8%) | 8 (15.1%) | |
Lymphoma or myeloma, n (%) | 4 (8.5%) | 6 (11.3%) | |
Disease Risk Index (DRI) overall | NS | ||
Low, n (%) | 3 (6.7%) | 2 (4.4%) | |
Intermediate, n (%) | 5 (12.2%) | 7 (15.5%) | |
High, n (%) | 29 (70.7%) | 32 (63.4%) | |
Very high, n (%) | 4 (9.8%) | 4 (8.9%) | |
Donor Type | |||
MSD, n (%) | 13 (27.7%) | 11 (20.8%) | NS |
Haplo, n (%) | 34 (72.3%) | 42 (79.2%) | NS |
1 Locus, n (%) | 1 (2.1%) | 0 (0%) | |
2 Locus, n (%) | 2 (4.3%) | 3 (5.7%) | |
3 Locus, n (%) | 31 (65.9%) | 39 (73.6%) | |
Engraftment | |||
WBC + days, median (range) | 14 (10–22) | 12 (10–24) | |
PLT + days, median (range) | 14 (7–32) | 13.5 (8–63) | |
Cells in allograft | |||
CD34+ (× 106/kg), median (range) | 1.92 (0.62–5.85) | 3.14 (0.64–6.85) | 0.002 |
CD3+ T (× 108/kg), median (range) | 2.31 (0.61–3.79) | 2.63 (0.82–5.79) | NS |
CD4+ (× 108/kg), median (range) | 1.21 (0.32–2.12) | 1.49 (0.43–3.42) | NS |
CD8+ (× 108/kg), median (range) | 0.72 (0.15–1.87) | 0.92 (0.31–2.29) | NS |